Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
Search results for: back pain
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
The Case for Integrated Musculoskeletal Care Teams
Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…
The 2020 ARP Merit Awards & ACR Distinguished Fellows
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
Study Elucidates Potential Flare Pathways in Rheumatoid Arthritis
Research in The New England Journal of Medicine has opened new avenues for exploring the pathophysiology of disease flares in rheumatoid arthritis.1 Through longitudinal genomic analysis, researchers have identified a naive B cell signature prior to rheumatoid arthritis flares, as well as a type of mesenchymal cell, that may play an important role in flare…
The Personal Side of COVID-19: A Q&A with Elna Schiopu, MD
Dr. Schiopu has experienced the COVID-19 pandemic response from both clinical and research perspectives. She recently discussed her experiences with The Rheumatologist.
Biologics in Rheumatology: Revolution & Perspectives
A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.
Medicare’s Most Favored Nation Is My Least Favorite Notion!
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
Effects of Warfarin on Risk of Hip & Knee Replacement in OA Patients
The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 162
- Next Page »